Observational studyAmerican journal of respiratory and critical care medicine2021
Culture Conversion in Patients Treated with Bedaquiline and/or Delamanid. A Prospective Multicountry Study.
Erratum issued Registry-linked trialAbstract readObservational Study
In one paragraph
Observational study in American journal of respiratory and critical care medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT03259269 (endTB), which is not on this map. Cited by 36 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 2 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
endTB (Expand New Drugs for TB) Observational Study: Treatment of MDR-TB With Regimens Containing Bedaquiline or Delamanid
Who cites it
36 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- Prevalence of hepatitis B, C, and D virus infection in Haiti: A systematic review and meta-analysis.Frontiers in public health · 2022Pooled it
- Effectiveness of Bedaquiline Use beyond Six Months in Patients with Multidrug-Resistant Tuberculosis.American journal of respiratory and critical care medicine · 2023Trial
- Assessing Prolongation of the Corrected QT Interval with Bedaquiline and Delamanid Coadministration to Predict the Cardiac Safety of Simplified Dosing Regimens.Clinical pharmacology and therapeutics · 2022Trial
- Culture conversion and drug susceptibility in drug-resistant pulmonary tuberculosis with type 2 diabetes mellitus on oral regimens.World journal of experimental medicine · 2026Article
- Molecular Mechanisms of Resistance and Treatment Efficacy of Delamanid AgainstHealth science reports · 2026Review
- Epidemiologic and clinical characteristics ofFrontiers in cellular and infection microbiology · 2026Article
- An Integrated Data-Driven Model for Clinical Phenotyping of Tuberculosis Disease Severity.medRxiv : the preprint server for health sciences · 2025Article
- Extensively Drug-Resistant Tuberculosis with Conflicting Resistance Testing Results, Lesotho.Emerging infectious diseases · 2025Article
- Treatment outcomes in cavitary multidrug-resistant/rifampicin-resistant tuberculosis and risk factors for cavity closure: a retrospective cohort study in Southwest China.Scientific reports · 2025Article
- Traditional and Short Course Treatment for Multidrug-Resistant Tuberculosis: A Comparative Study in National Referral Centers.Tanaffos · 2025Article
- Evaluation of a short, all oral treatment regimen including bedaquiline, delamanid, linezolid, clofazimine, and pyrazinamide named "Regimen C" for pre-XDR tuberculosis in Niger.Frontiers in tuberculosis · 2025Article
- Low body mass index as a predictor of sputum culture conversion and treatment outcomes among patients receiving treatment for multidrug-resistant tuberculosis in Lesotho.Global health action · 2024Article
- Predictors of early and interim culture un-conversion in multidrug-resistant/rifampicin-resistant tuberculosis: a retrospective multi-center cohort study in China.Antimicrobial resistance and infection control · 2024Article
- Safety and Effectiveness of 3 Novel All-Oral Shortened Regimens for Rifampicin- or Multidrug-Resistant Tuberculosis in Kazakhstan.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- Sputum culture reversion in longer treatments with bedaquiline, delamanid, and repurposed drugs for drug-resistant tuberculosis.Nature communications · 2024Observational
- Study of Culture Conversion in Drug-Resistant Pulmonary Tuberculosis on All-Oral Longer Regimen at IGIMS, Patna.Journal of pharmacy & bioallied sciences · 2024Article
- Outcomes of WHO-conforming, longer, all-oral multidrug-resistant TB regimens and analysis implications.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2023Observational
- Resistance Profiles to Second-Line Anti-Tuberculosis Drugs and Their Treatment Outcomes: A Three-Year Retrospective Analysis from South India.Medicina (Kaunas, Lithuania) · 2023Article
- Mapping Research Trends of Medications for Multidrug-Resistant Pulmonary Tuberculosis Based on the Co-Occurrence of Specific Semantic Types in the MeSH Tree: A Bibliometric and Visualization-Based Analysis of PubMed Literature (1966-2020).Drug design, development and therapy · 2023Review
Corrections and comments
- Commented on by
- Erratum issued
- Erratum issued
Authors and funding
28 authors.
Molly F FrankeDepartment of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts.
Palwasha KhanInteractive Research and Development, Karachi, Pakistan.
Cathy HewisonMedical Department, Doctors Without Borders, Paris, France.
Uzma KhanInteractive Research and Development, Karachi, Pakistan.
Helena HuergaField Epidemiology Department, Epicentre, Paris, France.
Kwonjune J SeungPartners In Health, Boston, Massachusetts.
Michael L RichPartners In Health, Boston, Massachusetts.
Khin ZarliMedical Department, Doctors Without Borders, Yangon, Myanmar.
Nazgul SamievaMedical Department, Doctors Without Borders, Bishkek, Kyrgyzstan.
Lawrence OyewusiPartners In Health, Maseru, Lesotho.
Parvati NairMedical Department, Doctors Without Borders, Minsk, Belarus.
Mishaz MudassarInteractive Research and Development, Karachi, Pakistan.
Nara MelikyanField Epidemiology Department, Epicentre, Paris, France.
Putri LenggogeniInteractive Research and Development, Jakarta, Indonesia.
Leonid LeccaPartners In Health, Lima, Peru.
Andargachew KumsaPartners In Health, Addis Ababa, Ethiopia.
Munira KhanInteractive Research and Development, Johannesburg, South Africa.
Shirajul IslamInteractive Research and Development, Dhaka, Bangladesh.
Kerow HusseinMedical Department, Doctors Without Borders, Nairobi, Kenya.
Wisny DocteurPartners In Health, Cange, Haiti.
Nino ChumburidzeMedical Department, Doctors Without Borders, Sokhumi, Georgia.
Elmira BerikovaPartners In Health, Astana, Kazakhstan; and.
Hakob AtshemyanMedical Department, Doctors Without Borders, Yerevan, Armenia.
Sidney AtwoodBrigham and Women's Hospital, Boston, Massachusetts.
Manzurul AlamInteractive Research and Development, Dhaka, Bangladesh.
Saman AhmedInteractive Research and Development, Karachi, Pakistan.
Mathieu BastardField Epidemiology Department, Epicentre, Paris, France.
Carole D MitnickDepartment of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdolescentAdultAgedAged, 80 and overAntitubercular AgentsBacterial ProteinsChildCohort StudiesDiarylquinolinesFemaleHumansMaleMiddle AgedNitroimidazolesOxazolesProspective StudiesAntitubercular AgentsARR-2 protein, BacteriaBacterial ProteinsbedaquilineDiarylquinolinesNitroimidazolesOxazolesextensively drug-resistant tuberculosisinterim outcomemultidrug-resistant tuberculosisrifampicin-resistant tuberculosissputum conversion
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
NCT03259269ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.